Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial

• Published in: Clinical microbiology and infection Vol. 14; no. 4; pp. 307 - 314
• Main Authors: Rodloff, A.C., Leclercq, R., Debbia, E.A., Cantón, R., Oppenheim, B.A., Dowzicky, M.J.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Elsevier Ltd 01.04.2008; Blackwell Publishing Ltd; Blackwell
• Subjects: Acinetobacter baumannii; Anti-Bacterial Agents - pharmacology; Antibacterial agents; Antibiotics. Antiinfectious agents. Antiparasitic agents; antimicrobial resistance; Biological and medical sciences; Drug Resistance, Bacterial; Enterococcus faecalis; Europe; Europe - epidemiology; Gram-Negative Bacteria - classification; Gram-Negative Bacteria - drug effects; Gram-Negative Bacteria - isolation & purification; Gram-Negative Bacterial Infections - epidemiology; Gram-Negative Bacterial Infections - microbiology; Gram-Positive Bacterial Infections - epidemiology; Gram-Positive Bacterial Infections - microbiology; Gram-Positive Cocci - classification; Gram-Positive Cocci - drug effects; Gram-Positive Cocci - isolation & purification; Humans; Infectious diseases; Medical sciences; Microbial Sensitivity Tests; Minocycline - analogs & derivatives; Minocycline - pharmacology; MRSA surveillance; Pharmacology. Drug treatments; Population Surveillance - methods; Staphylococcus aureus; tigecycline; Italy; United Kingdom; France; Europe; Germany; Spain; MRSA surveillance; Acinetobacter baumannii; antimicrobial resistance; Europe; tigecycline; Glycylcycline derivatives; Drug susceptibility test; Neisseriaceae; Infection; Antibiotic; Surveillance; Bacteria; Micrococcales; Micrococcaceae; Antibacterial agent; Tigecycline; Comparative study; Staphylococcus aureus
• ISSN: 1198-743X; 1469-0691
• DOI: 10.1111/j.1469-0691.2007.01943.x

As part of the tigecycline evaluation and surveillance trial (TEST), bacterial isolates were collected from 39 centres in France, Germany, Italy, Spain and the UK between January 2004 and August 2006. Antimicrobial susceptibilities were determined according to CLSI guidelines. Italy had the highest rate of methicillin-resistant Staphylococcus aureus (36.4%), and was the only country to report vancomycin-resistant Enterococcus faecalis (8.6%). Tigecycline was the only agent to which all Gram-positive isolates were susceptible. For many of the Gram-negative organisms collected, antimicrobial susceptibilities were lowest among isolates from Italy and highest among isolates from Spain. The notable exception was Acinetobacter baumannii, where the poorest susceptibility profile was among isolates from Spain. For A. baumannii, MIC90s of imipenem varied from 1 mg/L for isolates in France and Germany to ≥32 mg/L for isolates from Italy and Spain. Tigecycline was the only agent to maintain an MIC90 of ≤1 mg/L against isolates from all five countries. The in-vitro activity of tigecycline against both Gram-positive and Gram-negative isolates may make it valuable in the treatment of hospital infections, including those caused by otherwise antimicrobial-resistant organisms.